CoronaryAtlas logo
CoronaryAtlas
antiphospholipid antibodies
Pathway / Coagulation & thrombus formation

antiphospholipid antibodies

protein

Antiphospholipid antibodies induce a hypercoagulable state and thrombosis, causing MI in young patients.

Pathway placement
Cascade stepCoagulation & thrombus formation
Confidencehigh
RationaleAutoantibodies driving hypercoagulable state; thrombosis in young STEMI patients.
Also acts inPlatelet activation
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresNon-Type-I-associated
R — rupture / Type-I
—
C — non-Type-I
58
A — assay feasibility
68
E — evidence strength
48
T1DI (composite)
9
Specificity differential (R−C)-43.3
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationn/a
2anemia / acute blood lossn/a
2hypovolemia / dehydrationn/a
2tachyarrhythmiamag 1
2hypoxemia / respiratory failuren/a
2hypertensive emergencymag 2
2high-demand / peri-operative stressn/a
3sudden cardiac deathn/a
4aPCI-related periproceduraln/a
4bstent thrombosismag 2
4cin-stent restenosismag 2
5CABG-relatedn/a
Coverage: 4/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 10 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(2)